Cervical cancer(CC)is one of the most common gynecological cancers,ranking fourth in incidence and mortality rates among women worldwide and second in China[1].Approximately 15%-61%of patients with CC develop recurren...Cervical cancer(CC)is one of the most common gynecological cancers,ranking fourth in incidence and mortality rates among women worldwide and second in China[1].Approximately 15%-61%of patients with CC develop recurrent or metastatic(r/m)disease in the first two years after initial therapy completion,with a 5-year survival rate of 17%[2].Platinum-based chemotherapy is the first-line treatment for r/mCC.展开更多
基金supported by the CSPC Zhongqi Pharmaceutical Technology(Shijiazhuang)Co.,Ltd.
文摘Cervical cancer(CC)is one of the most common gynecological cancers,ranking fourth in incidence and mortality rates among women worldwide and second in China[1].Approximately 15%-61%of patients with CC develop recurrent or metastatic(r/m)disease in the first two years after initial therapy completion,with a 5-year survival rate of 17%[2].Platinum-based chemotherapy is the first-line treatment for r/mCC.
